Selected References:
- American College of Obstetricians and Gynecologists (ACOG). 2018. Committee Opinion No. 753: Assessment and Treatment of Pregnant Women with Suspected or Confirmed Influenza. Obstet Gyn 132(4):e169-e173.
- Aoki FY, et al. 2013. The use of antiviral drugs for influenza: A foundation document for practitioners. Can J Infect Dis Med Microbiol. 24(Suppl C) :1-15.
- Cruz MP. 2011. Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia. P & T : a peer-reviewed journal for formulary management, 36(8):489–492.
- Damkier, P & Videbech, P. 2018. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. CNS Drugs 32:351–366.
- 2011. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm
- Greenberg, WM & Citrome, L. 2017. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. Clin Pharmacokinet 56:493–503.
- Highlights of prescribing information contraindications LATUDA. 2017. Retrieved June 27, 2022, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/200603s26s27lbl.pdf.
- Kantrowitz JT, Citrome L. 2012. Lurasidone for schizophrenia: what’s different? Expert Rev Neurother. 12(3):265-73.
- Keightley P, et al. 2020. Lurasidone in lactation: A case study with laboratory and clinical outcomes. Aust N Z J Psychiatry. 54:1035–1036.
- Montiel C, et al. 2022 Perinatal use of lurasidone for the treatment of bipolar disorder. Exp Clin Psychopharmacol. 30(2):249-252.
- Terrana, N, et al. 2015. Pregnancy Outcomes Following In Utero Exposure to Second-Generation Antipsychotics: A Systematic Review and Meta-Analysis. Journal of Clinical Psychopharmacology, 35(5):559–565.
